Posted by Michael Wonder on 23 Feb 2020
FDA approves Lundbeck’s Vyepti (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine
22 February 2020 - In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), Vyepti met its primary endpoint: decrease in mean monthly migraine days over months.
H. Lundbeck today announced that Vyepti (eptinezumab-jjmr) has been approved by the U.S. FDA for the preventive treatment of migraine in adults and will be available in April 2020.
The recommended dose is 100 mg every 3 months; some patients may benefit from a dose of 300 mg. Vyepti is the first FDA-approved intravenous treatment for migraine prevention.
